Merifin Capital

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

Launched in 2013 in France, Flayr is a unique place for shopping discoveries, allowing people to discover outsourced and crowdsourced edgy little brands and take benefit of great deals on big brands. Flayr is very user-centric, designed only to fulfill their users' every needs. Flayr is developped in Paris, Caen (yes, Caen, Normandy-based city somewhere in France is the new Palo Alto) & USA by Olivier, Nicolas, Philippe, Jerome, Pierre, Delphine, Clémence, Arnaud, Valentin, Jérôme, Antoine, Antoine, Julie, Nabil, Tiphaine, Guillaume, Julien, Isaline, Romain, David, Cassio, and Arthur. France finally found its fourth F: "Fashion, Fragrance, Fromage and Flayr"!

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Plastic Logic Ltd is a manufacturer of plastic electronics, specializing in the development and production of flexible displays and devices. The company, based in Cambridge, United Kingdom, and with operations in Dresden, Germany, offers a range of high-quality, lightweight, and shatterproof electrophoretic displays in both color and monochrome. These displays are utilized in various applications, including mobile devices such as smartphones, e-readers, and tablets, as well as in signage, wristwatches, and automotive products. Plastic Logic serves original equipment manufacturers (OEMs), system integrators, and device manufacturers across the UK, Germany, Russia, and other international markets. The company has established a strategic partnership with UST Global Inc. and operates a pioneering facility that serves as the world's first commercial, volume production site for organic electronics. Through its open pilot line, Plastic Logic also collaborates with third-party companies, sharing its expertise in the industrialization and manufacturing of flexible electronics.

Metara manufactures chemical metrology tools for semiconductor industry that are used in monitoring and controlling chemical processes. Its products include sentry trace contamination metrology system, which monitors benign chemistries for trace contaminants; and sentry chemical composition metrology system, which monitors copper electroplating and cobalt bath chemistries. The company also offers sentry harsh chemistry metrology system, an analysis solution for harsh chemistries used in semiconductor manufacturing processes; and inline mass spectrometer, a chemical metrology solution that determines chemical composition and potential yield-or process-limiting contaminants. Metara Inc. was founded in 2000 and is headquartered in Sunnyvale, California.

DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. Established in 1992 and headquartered in Berkeley Heights, New Jersey, the company specializes in oral treatments that influence various phases of cell cycle control. Its oncology pipeline features several promising candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently undergoing Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase (PLK) inhibitor in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, in combination studies for patients with BRCA mutations, along with ongoing Phase III trials for acute myeloid leukemia. The company collaborates with the University of Texas MD Anderson Cancer Center to assess the safety and efficacy of its treatments in hematological malignancies and has partnered with ManRos Therapeutics for the development of oral seliciclib capsules aimed at treating cystic fibrosis.

Optiva develops and manufactures nanomaterials for use in optical, electro-optical, and semiconductor applications.